Citadel Advisors’s Intersect ENT, Inc XENT Stock Holding History

Citadel Advisors’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,100	Closed	-$384K	–	15352
2021 Q3	$384K	Sell	14,100 -31,600	-69%	-$781K	﹤0.01%	10513
2021 Q2	$781K	Buy	45,700 +7,300	+19%	+$137K	﹤0.01%	9006
2021 Q1	$802K	Buy	38,400 +6,900	+22%	+$159K	﹤0.01%	8640
2020 Q4	$721K	Buy	+31,500	New	+$600K	﹤0.01%	7447
2020 Q3	–	Sell	-10,600	Closed	-$144K	–	11017
2020 Q2	$144K	Sell	10,600 -2,000	-16%	-$23.3K	﹤0.01%	8775
2020 Q1	$149K	Buy	+12,600	New	+$279K	﹤0.01%	8303
2019 Q2	–	Sell	-10,600	Closed	-$341K	–	10121
2019 Q1	$341K	Sell	10,600 -17,300	-62%	-$535K	﹤0.01%	7426
2018 Q4	$786K	Sell	27,900 -4,800	-15%	-$141K	﹤0.01%	5684
2018 Q3	$940K	Buy	32,700 +17,600	+117%	+$529K	﹤0.01%	5667
2018 Q2	$565K	Buy	15,100 +5,000	+50%	+$196K	﹤0.01%	6173
2018 Q1	$397K	Buy	+10,100	New	+$369K	﹤0.01%	6282

Citadel Advisors's XENT Position: Q2 2022 in Review

Citadel Advisors sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 140,474 shares — an estimated $3.94M sold.

Citadel Advisors first reported a position in XENT in Q3 2014 and held it in 27 quarters. The position peaked at $22.6M in Q4 2020. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Citadel Advisors reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Citadel Advisors sold 140,474 Intersect ENT, Inc shares in Q2 2022, an estimated $3.94M.
Citadel Advisors first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 27 quarters.
Citadel Advisors's Intersect ENT, Inc position peaked at $22.6M in Q4 2020.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.